April 21, 2010, Lincoln, NE: In preparation for potential clinical use, a paper reporting a safety and toxicity study of the near infrared dye IRDye 800CW was reported April 8th in the online section of Molecular Imaging and Biology. The manuscript entitled, "Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats" reported no pathological evidence of toxicity based on the hematologic, clinical chemistry, and histopathologic analyses performed in the study.
"With the current progress in NIR fluorescent instrument development, IRDye 800CW could impact translational molecular imaging by providing a functionalized dye for labeling a new class of contrast imaging agents," says Michael Olive, LI-COR's vice president of translational research and co-author of the paper.
To download the publication, click here.
LI-COR is preparing to submit a drug master file on IRDye 800CW to the U.S. food and Drug administration and anticipates having dye made in compliance with cGMP regulations in 2010.
LI-COR Biosciences is engaged in the design, manufacture, and marketing of high quality, innovative instruments, software, reagents, and integrated systems for biotechnology, drug discovery, plant biology, and environmental research. Building upon the strengths of its personnel, LI-COR Biosciences has grown to include more than 300 employees at its headquarters in Lincoln, NE and subsidiaries in Bad Homburg, Germany and Cambridge, UK. LI COR systems are used in over 100 countries worldwide in studies ranging from global climate change to cancer research. LI COR Biosciences is a privately held company and is ISO 9001 certified. Further information can be obtained at www.licor.com.
D. Doc Chaves
Director of Marketing Communications
LI-COR Biosciences
4647 Superior St.
Lincoln, NE 68504
tel: 402.467.0750
doc.chaves@licor.com